Melatonin-A New Prospect in Prostate and Breast Cancer Management.

Autor:	Anim-Koranteng C; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Shah HE; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Bhawnani N; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Ethirajulu A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Alkasabera A; General Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Onyali CB; Internal Medicine, EHA Clinics, Abuja, NGA., Mostafa JA; Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Sep 20; Vol. 13 (9), pp. e18124. Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021).
DOI:	10.7759/cureus.18124
Abstrakt:	Cancer is a known cause of mortality globally. The management of cancer has been influenced periodically by diverse scientific research for early detection to promote remission and improve quality of life. One of these advancements is the prospect of melatonin (n-acetyl-5-methoxytryptamine) in managing prostate and breast cancers. Melatonin exerts its oncostatic effect by inhibiting angiogenesis, preventing cancer spread and growth, and improving the sensitivity of cancer cells to radiation and chemotherapy in both prostate and breast cancer. This review aims to highlight some of the current studies on melatonin's effect on prostate and breast cancers. We reviewed articles and two randomized controlled trials (RCT) that highlighted the mechanism of melatonin in combating tumorigenesis of these cancers. Articles and RCT studies were obtained by searching PubMed using regular and Medical Subject Heading (MeSH) keyword search strategy. The majority of the articles reviewed supported the use of melatonin in cancer management since inhibition of angiogenesis, cancer proliferation, invasion of normal cells by tumor cells, and improvement in chemotherapeutic and radiation therapy were achieved with its use. In addition, melatonin was also protective against prostate and breast cancers in the general population. Despite the benefits of melatonin in cancer management, most of the studies done were in vivo and in vitro studies, and more studies in human subjects are encouraged to confirm the positive therapeutic use of melatonin. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Anim-Koranteng et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu